Juston C. Weems

Department of Biochemistry and Molecular Biology, Research & Development, Transplant Genomics, Inc, 1001 NW Technology Drive, Suite 110, Lees Summit, MO 64086, United States

Publications

Letter
Technology-driven Performance Improvement of a Biomarker Panel in Kidney Transplant: OmniGraf
Author(s): Patricia M. West-Thielke, Cortney C. Miller, Winston Ally, April Sutton, Rohita Sinha, Mikaela Miller, Steve Kleiboeker and Juston C. Weems*

Here we present the impact of the transition from TruGraf microarray to TruGraf PCR on the performance of OmniGraf, the combination of TruGraf Gene expression and TRAC dd-cfDNA tests. Using the same biopsy-paired samples as previously published, we saw an improvement in the NPV from 88% to 94% when both assays were negative. Perhaps more importantly, we observed an increase in the PPV from 81% to 89% when both tests were positive. False negative results were reduced from 31% to 17%, while true negative results improved from 74% to 81%. Within our cohorts, we observed 26.2% of results to be positive for one test and negative for the other: 11.7% showed elevated TRAC (+) and a negative TruGraf (-); 14.5% showed a TruGraf positive (+) and low TRAC score (-). The previous publication demonstrated that TruGraf microarray was significantly better at detecting subclinical TCMR and.. Read More»
DOI: 10.37421/2161-0991.22.12.207

Abstract HTML PDF